Chinese biotech deal flow is increasingly driven by authentic innovation rather than legacy concerns around imitation and IP ...

Sandoz Inc. and Fougera Pharmaceuticals will settle three Connecticut federal cases, paying $400 million over seven years plus ~$50 million to prior settlors, pending approvals from all participating ...

Rumored tie-up implies acquirer skepticism versus target premium, with AstraZeneca shares falling sharply while BMS rose, reflecting concerns about value transfer and integration risk. A major ...

AstraZeneca and BMS held merger talks, Incubate's John Stanford on fixing the US pharma ecosystem, and why real-time clinical trial data matters. Welcome to Pharmaceutical Executive Daily, your quick ...

Please check back later for more content.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that FDA granted approval of Simtriyo (centanafadine), a once-daily extended-release ...

Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Since then, that mindset has continued to grow at AbbVie.

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

Earlier this year, a report from Pharmaceutical Executive detailed the ways in which China is becoming an essential R&D partner for pharma and biotech companies. According to the ...